OncoDNA announces screening collaboration with Kura Oncology
- OncoDNA to support patient enrolment for Kura Oncology’s Phase II trial of tipifarnib
- Agreement demonstrates OncoDNA’s biopharma partnership strategy
Under the agreement, OncoDNA will support patient enrolment for Kura’s ongoing HRAS tipifarnib trial in patients with HRAS mutant head and neck squamous cell carcinomas (HNSCC). Tipifarnib is an inhibitor of farnesylation, a key cell signalling process implicated in cancer initiation and resistance to standard therapies. Tipifarnib has demonstrated encouraging clinical activity, including durable responses in HRAS mutant HNSCC. OncoDNA provides physicians in
In addition to screening for HNSCC patients with HRAS mutations at clinical sites participating in Kura studies, the Company will also support Kura’s other recruitment efforts. OncoDNA offers community oncologists comprehensive cancer biomarker analyses and treatment recommendations tailored to the molecular profile of individual patients’ tumors. OncoDNA will inform physicians with HNSCC patients carrying HRAS mutations of potential treatment and clinical trial options, including tipifarnib. Additional information about Kura’s currently ongoing RUN-HN trial can be found at clinicaltrials.gov (identifier: NCT02383927). The financial terms of the agreement have not been disclosed.
Jean-Pol Detiffe, Chief Executive Officer of OncoDNA, said: “We are excited to announce this collaboration with
OncoDNA is a private, oncology-focused healthcare technology company that combines advanced, comprehensive testing of all clinically relevant cancer biomarkers (DNA, RNA and protein profiles) from both solid and liquid biopsies with a proprietary cancer treatment knowledge database called OncoKDO™ that continuously ‘learns’ from cutting-edge, validated, scientific and medical advances. This one-stop-shop analysis and interpretation service gives oncologists actionable results to enable the selection of treatments tailored to an individual patient’s cancer profile. OncoDNA also works in collaboration with the biopharma industry to develop and deliver the treatments of tomorrow by assisting with design, enrolment and assessment of clinical trials as well as increasing access to approved precision medicines. The company is based in Gosselies,
Head and neck cancer is one of the leading causes of cancer-related deaths worldwide, with squamous cell carcinomas accounting for most head and neck cancers. The relapsed and/or refractory HNSCC patient population has an overall survival of approximately 6-8 months and few therapeutic options. New therapies for HNSCC, including immunotherapy, typically show a response rate in the range of 10-20%. HRAS is a proto-oncogene that has been implicated in the development and progression of HNSCC. HRAS mutant HNSCC has an estimated annual incidence of approximately 2,800 to 3,400 patients in the U.S. and represents a significant unmet medical need.
|OncoDNA||+32 (0) 71 18 35 00|
|Jean-Pol Detiffe, CEO|
|Pierre Flamant, CFO|
|Consilium Strategic Communications||+44 (0)20 3709 5700|
|Amber Fennell, Sukaina Virji, Nicholas Brown, Hendrik Thysemail@example.com|
Source: Kura Oncology, Inc.